K63.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM K63.1 became effective on October 1, 2021. This is the American ICD-10-CM version of K63.1 - other international versions of ICD-10 K63.1 may differ. A type 1 excludes note is a pure excludes.
I73.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM I73.9 became effective on October 1, 2018. This is the American ICD-10-CM version of I73.9 - other international versions of ICD-10 I73.9 may differ.
Z71- Persons encountering health services for other counseling and medical advice, not elsewhere classified Z71.89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM Z71.89 became effective on October 1, 2020.
Z71.89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM Z71.89 became effective on October 1, 2020. This is the American ICD-10-CM version of Z71.89 - other international versions of ICD-10 Z71.89 may differ. Z codes represent reasons for encounters.
For each injection given, the procedure code which accurately reflects the products used and 20610 (Arthrocentesis, aspiration and/or injection, major joint or bursa (e.g., shoulder, hip, knee, subacromial bursa); without ultrasound guidance), may be billed when viscosupplementation of the knee is performed.
All settings should bill Synvisc-One as 3 units of code J7322.
The new HCPC code, J7325, is reported for both Synvisc and Synvisc One, the injection code is easy, and so we will start there— Bill using CPT 20610. The reporting of Synvisc is dependent on what drug you are using. Synvisc One: is a concentrated dose, is only administered one time and is reported with 48 units.
Billing the injection procedure The procedure code (CPT code) 20610 may be billed for the intraarticular injection.
Viscosupplementation (J7325) for osteoarthritis of the knee should be reported with injection procedure code 20610.
The Hotline program is available Monday through Friday from 9:00 AM to 8:00 PM ET at 1-866 HYMOVIS® (1-866-496-6847).
Medicare reimburses HYMOVIS at ASP+6% Check the CMS web site for current Medicare reimbursement amounts for HYMOVIS at: www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html Contact private payers or consult contracts for their reimbursement amounts.
SYNVISC is a viscosupplement injection that supplements the fluid in your knee to help lubricate and cushion the joint, and can provide up to six months of osteoarthritis knee pain relief with three injections.
The CPT code 20611 is for an arthrocentesis, aspiration and/or injection, major joint or bursa (e.g., shoulder, hip, knee or subacromial bursa with ultrasound guidance, with permanent recording and reporting). The code is billed twice because this was a bilateral procedure.
Does Medicare Pay for Knee Gel Injections? Yes, Medicare will cover knee injections that approved by the FDA. This includes hyaluronan injections. Medicare does require that the doctor took x-rays to show osteoarthritis in the knee.
SYNVISC Reimbursement Billing CodesSynvisc-One and SYNVISC Billing CodesICD-10-CMSynvisc-One48 in Units field of CMS-1500 Claim form or electronic equivalentSYNVISC16 in Units field of CMS-1500 Claim form or electronic equivalentCPT22 more rows
For bilateral administration of HYALGAN, some payers may require modifier “-50” (bilateral procedure) to be documented after CPT code 20610. In addition payers may require EJ modifier, usually following the first injection, to indicate subsequent injections in a series of injections.
CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.
This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for Viscosupplementation Therapy for Knee. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy.
Viscosupplementation therapy is part of the therapy used in the treatment of osteoarthritis of the knee. Osteoarthritis results from articular cartilage failure due to the complex interplay of genetic, metabolic, biochemical and biomechanical factors with a secondary component of inflammation.